United KingdomDr. Amir Khan, a practicing NHS GP, warns that individuals with diabetic eye disease who take weight loss medications such as GLP-1 receptor agonists (e.g., Wegovy and Mounjaro) may face an increased risk of worsening their condition and potentially losing their sight. The warning stems from concerns that the rapid drop in blood sugar levels caused by these drugs, combined with weight loss, could negatively impact the small blood vessels in the eyes. Khan explains that while the exact mechanism is unclear, the potential risk is significant enough to warrant caution. Additionally, he notes that doctors are monitoring for possible thyroid-related issues linked to these medications, citing animal studies showing an increased risk of thyroid cancer, though no conclusive evidence exists in humans. Patients with a personal or family history of thyroid cancer are advised to avoid these drugs due to the potential risk.
Bias read (Center): The article presents a health warning regarding the potential risks of weight loss medications for individuals with pre-existing conditions, specifically diabetic eye disease. There is no indication of political bias, ideological framing, or partisan emphasis. The content focuses on medical advice,
